Introduction/Background High-grade serous carcinoma (HGSC) is most of the time diagnosed in later stages. New assumptions show that HGSC ovarian cancers have their origin in the fallopian tubes, as tubal malignant cells travel at the adjacent ovary. This study aimed to identify the origins and clinical characteristics of women with pelviabdominal tumor.

Methodology Forty-five cases of serous pelviabdominal tumor were eligible and analyzed retrospectively in our department between 2019 and 2022. Clinical characteristics including age, family history of malignancy, menopausal status, number of births, and serum levels of cancer antigen (CA)-125 were collected.

Results Intraoperatively, we performed total hysterectomy with bilateral salpingo-oophorectomy and pelvic lymphadenectomy, viscerolysis, adhesiolysis and partial omentectomy. After mass biopsy, the diagnosis was HGSC, FIGO stage IIIC of which 26 (57.77%) patients had ovarian HGSC, and 19 (42.22%) cases had tubal HGSC. The mean age of the patients with ovarian HGSC was 57 and the mean age of the ones with tubal HGSC was 58. From the total number of patients with ovarian HGSC only 20 (76.92%), and only 11 (57.89%) diagnosed with tubal HGSC had history of malignancy, without any statistically significance. All the patients from ovarian HGSC (n=26, 100%), and only 6 (31.57%) patients suffering from tubal HGCS were at menopause, without any statistically significance. The mean number of births was 2 and the difference between CA-125 for both HGSC was also not statistically significant.

Conclusion The clinical data from both ovarian and tubal HGSC were similar, without any significant difference suggesting that both types of patients could receive a similar therapeutic scheme. Finally, this study shows the importance of determining the tumor’s origin in order to achieve a proper management in the shortest amount of time.

Disclosures The authors declare no financial disclosures or conflicts of interest.